TME Pharma N.V. (ALTME) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.353x

Based on the latest financial reports, TME Pharma N.V. (ALTME) has a cash flow conversion efficiency ratio of 0.353x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-557.00K ≈ $-651.19K USD) by net assets (€-1.58 Million ≈ $-1.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TME Pharma N.V. (ALTME) net asset quality to measure how much of total assets are equity-financed.

TME Pharma N.V. - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how TME Pharma N.V.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TME Pharma N.V. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

TME Pharma N.V. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TME Pharma N.V. ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Readcloud Ltd AU:RCL	-0.153x
Carbine Resources Ltd AU:CRB	-0.045x
Capelli SA PA:ALCAP	0.001x
Bekasi Asri Pemula Tbk JK:BAPA	-0.003x
Data Storage Corp NASDAQ:DTST	-0.167x
Compass Group PLC LSE:CPG	0.258x
MBAK Energy Solutions Inc. NASDAQ:MBAK	N/A
TIANJIN JIN.PUB.U.H YC-10 F:TL6	N/A

Annual Cash Flow Conversion Efficiency for TME Pharma N.V. (2014–2025)

The table below shows the annual cash flow conversion efficiency of TME Pharma N.V. from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see TME Pharma N.V. market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€-1.58 Million ≈ $-1.85 Million	€-3.42 Million ≈ $-3.99 Million	2.164x	+175.37%
2024-12-31	€1.61 Million ≈ $1.89 Million	€-4.63 Million ≈ $-5.42 Million	-2.871x	-114.98%
2023-12-31	€-294.00K ≈ $-343.72K	€-5.63 Million ≈ $-6.59 Million	19.167x	+100.77%
2022-12-31	€-1.27 Million ≈ $-1.49 Million	€-12.14 Million ≈ $-14.20 Million	9.546x	+447.13%
2021-12-31	€4.50 Million ≈ $5.26 Million	€-12.38 Million ≈ $-14.47 Million	-2.750x	-305.25%
2020-12-31	€7.70 Million ≈ $9.00 Million	€-5.22 Million ≈ $-6.11 Million	-0.679x	-129.36%
2019-12-31	€-1.85 Million ≈ $-2.17 Million	€-4.29 Million ≈ $-5.01 Million	2.312x	+50.67%
2018-12-31	€-2.61 Million ≈ $-3.05 Million	€-4.00 Million ≈ $-4.68 Million	1.534x	+41.92%
2017-12-31	€-3.92 Million ≈ $-4.58 Million	€-4.24 Million ≈ $-4.95 Million	1.081x	-70.15%
2016-12-31	€-2.48 Million ≈ $-2.90 Million	€-8.99 Million ≈ $-10.51 Million	3.622x	+88.94%
2015-12-31	€-7.03 Million ≈ $-8.22 Million	€-13.48 Million ≈ $-15.76 Million	1.917x	-3.93%
2014-12-31	€-6.24 Million ≈ $-7.30 Million	€-12.46 Million ≈ $-14.57 Million	1.996x	--

About TME Pharma N.V.

PA:ALTME France Biotechnology

Market Cap

$6.73 Million

€5.76 Million EUR

Market Cap Rank

#27956 Global

#494 in France

Share Price

€0.06

Change (1 day)

-1.29%

52-Week Range

€0.05 - €0.11

All Time High

€1994.22